Home › Research › Treatments
O4‐04‐05: Aducanumab (BIIB037), an anti‐amyloid beta monoclonal antibody, in patients with prodromal or mild Alzheimer's disease: Interim results of a randomized, double‐blind, placebo‐controlled, phase 1b study
Jeff Sevigny, Ping Chiao, Leslie J. Williams, Tianle Chen, Yan Ling, John O'Gorman, Christoph Höck, Roger M. Nitsch et al.. Alzheimer s & Dementia, 2015-07-01
Topic: Drug trials: efficacy and safety
Plain-language summary
Aducanumab (BIIB037) is a human monoclonal antibody selective for aggregated forms of beta-amyloid peptide being investigated as a disease-modifying treatment for AD. This Phase 1b study is evaluating the safety, tolerability, pharmacokinetics, and pharmacodynamics of aducanumab in patients with prodromal or mild AD. Patients included in this multicenter, randomized, double-blind, placebo-controlled, multiple-dose study (PRIME; NCT01677572) were aged 50-90 years, had a positive florbetapir (F-AV-45) PET scan, and met clinical criteria for prodromal or mild AD. During the double-blind, placebo-controlled phase, patients received aducanumab or placebo once every 4 weeks for 52 weeks. In a staggered, ascending-dose design, patients were randomized to 1 of 7 treatment arms stratified by ApoE4 status (carrier/non-carrier). Primary endpoint was safety and tolerability. Secondary endpoints included change from baseline to Week 26 in brain beta-amyloid plaque burden measured by PET imaging. Cognition/functioning, including change from baseline on the Clinical Dementia Rating scale, was an exploratory endpoint. Interim analyses included: (1) subjects in all arms who completed the Week 26 visit, and (2) subjects in all arms who completed the Week 54 visit (results for placebo, 1, 3 and 10 mg/kg aducanumab at Week 54 available here, results for 6 mg/kg at Week 54 will be presented). Figure Dose-dependent ARIA was the main safety and tolerability finding. Aducanumab reduced beta-amyloid plaque in patients with prodromal or mild AD. A clinical signal was observed in exploratory analysis.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Sevigny, J., Chiao, P., Williams, L. J., Chen, T., Ling, Y., O'Gorman, J., et al. (2015). O4‐04‐05: Aducanumab (BIIB037), an anti‐amyloid beta monoclonal antibody, in patients with prodromal or mild Alzheimer's disease: Interim results of a randomized, double‐blind, placebo‐controlled, phase 1b study. Alzheimer s & Dementia. https://doi.org/10.1016/j.jalz.2015.07.367
Vancouver
Sevigny J, Chiao P, Williams LJ, Chen T, Ling Y, O'Gorman J, et al. O4‐04‐05: Aducanumab (BIIB037), an anti‐amyloid beta monoclonal antibody, in patients with prodromal or mild Alzheimer's disease: Interim results of a randomized, double‐blind, placebo‐controlled, phase 1b study. Alzheimer s & Dementia. 2015. doi:10.1016/j.jalz.2015.07.367.
BibTeX
@article{sevigny2015-204cb97e,
author = {Sevigny, Jeff and Chiao, Ping and Williams, Leslie J. and Chen, Tianle and Ling, Yan and O'Gorman, John and Höck, Christoph and Nitsch, Roger M. and others},
title = {{O4‐04‐05: Aducanumab (BIIB037), an anti‐amyloid beta monoclonal antibody, in patients with prodromal or mild Alzheimer's disease: Interim results of a randomized, double‐blind, placebo‐controlled, phase 1b study}},
journal = {Alzheimer s \& Dementia},
year = {2015},
doi = {10.1016/j.jalz.2015.07.367},
url = {https://doi.org/10.1016/j.jalz.2015.07.367}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record's author list ends in “et al.”, so not every author is named. Check the citation against the original before you use it.
Key findings
- Interim analyses included: (1) subjects in all arms who completed the Week 26 visit, and (2) subjects in all arms who completed the Week 54 visit (results for placebo, 1, 3 and 10 mg/kg aducanumab at Week 54 available here, results for 6 mg/kg at Week 54 will be presented).
New to this subject? Start with our plain-English guide: Treatments →
Study details
- Evidence strengthHigh
How this study scored 43/100
Published in a peer-reviewed journal. Scored zero for study design, sample size, effect reported and studied in people because the record does not state it. We have no data on journal's citation record, times cited, citations per year, impact for its field and year, cited by studies here, still being cited, senior author's track record, institution's track record and multicenter collaboration, so those were left out: it earned 25 of the 58 points we could judge it on, which is 43 out of 100.
| Component | Points | Why |
|---|---|---|
| Journal tier | 7 / 10 | Tier 3 — peer-reviewed journal (Alzheimer s & Dementia) |
| Journal's citation record | — / 4 | No journal record from OpenAlex — left out of this score |
| Study design | 0 / 12 | No study design recorded — scores zero, not guessed (not stated in the record — scored 0) |
| Strength of evidence | 5 / 5 | Rated “high” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 1 / 5 | 2015 — within 20 year(s) of the newest study here |
| Sample size | 0 / 4 | Participant count not stated — scores zero (not stated in the record — scored 0) |
| Effect reported | 0 / 3 | No effect size reported — scores zero (not stated in the record — scored 0) |
| Studied in people | 0 / 3 | Not stated whether this was studied in people — scores zero (not stated in the record — scored 0) |
| Randomized / blinded | 1 / 2 | Randomized (as stated in the record) |
| Times cited | — / 7 | No citation count (not found in OpenAlex) — left out of this score |
| Citations per year | — / 5 | No citation count or no year — left out of this score |
| Impact for its field and year | — / 6 | No field-weighted citation impact (OpenAlex has none yet) — left out of this score |
| Cited by studies here | — / 6 | Not yet checked against this library's citation graph — left out of this score |
| Still being cited | — / 4 | No yearly citation counts — left out of this score |
| Senior author's track record | — / 4 | Senior author's record not available — left out of this score |
| Institution's track record | — / 3 | No institution listed in OpenAlex — left out of this score |
| Multicenter collaboration | — / 3 | Institutions not listed — left out of this score |
| Indexed in PubMed | 1 / 2 | Not in PubMed, but has a DOI |
| Free to read | 0 / 2 | Behind a paywall — scores zero |
| Points | 25 / 58 | Scored on 11 of 20 parts. We have no data for the rest, so they are left out: 25 of the 58 points we could judge it on is 43 out of 100. |
| Total | 43 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
Free copy unknown: no free-copy check has an answer for this record yet. That does not mean it is paywalled.
Related
Studies in the library that share something with this one. The line above each title says what.
Related studies in Treatments from nearby years
Also tagged “monoclonal”
332 studies in the library carry the topic tag “monoclonal”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 332 tagged studies.